Abstract A015: Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages | Citedby Results | Cancer Immunology Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract A015: Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages

Cancer Immunol Res (2016) 4 (1_Supplement): A015.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Immunomodulating Effects of Fungal Beta-Glucans: From Traditional Use to Medicine

Hidde P. van Steenwijk
Aalt Bast
Alie de Boer

Nutrients (2021) 13 (4): 1333.

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

M. Thomas
P. Sadjadian
J. Kollmeier
J. Lowe
P. Mattson
J. R. Trout
M. Gargano
M. L. Patchen
R. Walsh
M. Beliveau
J. F. Marier
N. Bose
K. Gorden
F. Schneller

Investigational New Drugs (2017) 35 (3): 345.

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

C. E. Halstenson
T. Shamp
M. A. Gargano
R. M. Walsh
M. L. Patchen

Investigational New Drugs (2016) 34 (2): 202.